The DOI matches its Crossref record; 21 of the 21 references it cites were found in a registry or an index.
Phase 3 Studies Comparing Brodalumab with Ustekinumab in Psoriasis
Open accessAbstract
BACKGROUND: Early clinical studies suggested that the anti-interleukin-17 receptor A monoclonal antibody brodalumab has efficacy in the treatment of psoriasis. METHODS: In two phase 3 studies (AMAGINE-2 and AMAGINE-3), patients with moderate-to-severe psoriasis were randomly assigned to receive brodalumab (210 mg or 140 mg every 2 weeks), ustekinumab (45 mg for patients with a body weight ≤100 kg and 90 mg for patients >100 kg), or placebo. At week 12, patients receiving brodalumab were randomly assigned again to receive a brodalumab maintenance dose of 210 mg every 2 weeks or 140 mg every 2 weeks, every 4 weeks, or every 8 weeks; patients receiving ustekinumab continued to receive ustekinumab every 12 weeks, and patients receiving placebo received 210 mg of brodalumab every 2 weeks. The primary aims were to evaluate the superiority of brodalumab over placebo at week 12 with respect to at least a 75% reduction in the psoriasis area-and-severity index score (PASI 75) and a static physician's global assessment (sPGA) score of 0 or 1 (clear or almost clear skin), as well as the superiority of brodalumab over ustekinumab at week 12 with respect to a 100% reduction in PASI score (PASI 100). RESULTS: At week 12, the PASI 75 response rates were higher with brodalumab at the 210-mg and 140-mg doses than with placebo (86% and 67%, respectively, vs. 8% [AMAGINE-2] and 85% and 69%, respectively, vs. 6% [AMAGINE-3]; P<0.001); the rates of sPGA scores of 0 or 1 were also higher with brodalumab (P<0.001). The week 12 PASI 100 response rates were significantly higher with 210 mg of brodalumab than with ustekinumab (44% vs. 22% [AMAGINE-2] and 37% vs. 19% [AMAGINE-3], P<0.001). The PASI 100 response rates with 140 mg of brodalumab were 26% in AMAGINE-2 (P=0.08 for the comparison with ustekinumab) and 27% in AMAGINE-3 (P=0.007). Rates of neutropenia were higher with brodalumab and with ustekinumab than with placebo. Mild or moderate candida infections were more frequent with brodalumab than with ustekinumab or placebo. Through week 52, the rates of serious infectious episodes were 1.0 (AMAGINE-2) and 1.3 (AMAGINE-3) per 100 patient-years of exposure to brodalumab. CONCLUSIONS: Brodalumab treatment resulted in significant clinical improvements in patients with moderate-to-severe psoriasis. (Funded by Amgen; AMAGINE-2 and AMAGINE-3 ClinicalTrials.gov numbers, NCT01708603 and NCT01708629.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Ye, P., Rodriguez, F. H., Kanaly, S., Stocking, K. L., Schurr, J., Schwarzenberger, P., Oliver, P., Huang, W., Zhang, P., Zhang, J., et al. (2001) · The Journal of Experimental Medicine · doi:10.1084/jem.194.4.519 · Cited by 1,521
Psoriasis Vulgaris Lesions Contain Discrete Populations of Th1 and Th17 T Cells
Lowes, M. A., Kikuchi, T., Fuentes-Duculan, J., Cardinale, I., Zaba, L. C., Haider, A. S., Bowman, E. P., & Krueger, J. G. (2008) · Journal of Investigative Dermatology · doi:10.1038/sj.jid.5701213 · Cited by 1,082
Chronic Mucocutaneous Candidiasis in Humans with Inborn Errors of Interleukin-17 Immunity
Puel, A., Cypowyj, S., Bustamante, J., Wright, J. F., Liu, L., Lim, H. K., Migaud, M., Israel, L., Chrabieh, M., Audry, M., et al. (2011) · Science · doi:10.1126/science.1200439 · Cited by 1,056
Conti, H. R., Shen, F., Nayyar, N., Stocum, E., Sun, J. N., Lindemann, M. J., Ho, A. W., Hai, J. H., Yu, J. J., Jung, J. W., et al. (2009) · Journal of Experimental Medicine · doi:10.1084/jem.20081463 · Cited by 1,024
Brodalumab, an Anti–Interleukin-17–Receptor Antibody for Psoriasis
Papp, K. A., Leonardi, C., Menter, A., Ortonne, J.-P., Krueger, J. G., Kricorian, G., Aras, G., Li, J., Russell, C. B., Thompson, E. H. Z., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1109017 · Cited by 941
Self-citationDefinition of treatment goals for moderate to severe psoriasis: a European consensus
Mrowietz, U., Kragballe, K., Reich, K., Spuls, P., Griffiths, C. E. M., Nast, A., Franke, J., Antoniou, C., Arenberger, P., Balieva, F., et al. (2011) · Archives of Dermatological Research · doi:10.1007/s00403-010-1080-1 · Cited by 898
Nograles, K. E., Zaba, L. C., Guttman-Yassky, E., Fuentes-Duculan, J., Suárez-Fariñas, M., Cardinale, I., Khatcherian, A., Gonzalez, J., Pierson, K. C., White, T. R., et al. (2008) · British Journal of Dermatology · doi:10.1111/j.1365-2133.2008.08769.x · Cited by 804
Teunissen, M. B. M., Bos, J. D., Koomen, C. W., de Waal Malefyt, R., & Wierenga, E. A. (1998) · Journal of Investigative Dermatology · doi:10.1046/j.1523-1747.1998.00347.x · Cited by 570
Lebwohl, M. G., Bachelez, H., Barker, J., Girolomoni, G., Kavanaugh, A., Langley, R. G., Paul, C. F., Puig, L., Reich, K., & van de Kerkhof, P. C. M. (2014) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2013.12.018 · Cited by 515
Self-citationIL-17C regulates the innate immune function of epithelial cells in an autocrine manner
Ramirez-Carrozzi, V., Sambandam, A., Luis, E., Lin, Z., Jeet, S., Lesch, J., Hackney, J., Kim, J., Zhou, M., Lai, J., et al. (2011) · Nature Immunology · doi:10.1038/ni.2156 · Cited by 477
Genome-wide association study identifies a psoriasis susceptibility locus at TRAF3IP2
Ellinghaus, E., Ellinghaus, D., Stuart, P. E., Nair, R. P., Debrus, S., Raelson, J. V., Belouchi, M., Fournier, H., Reinhard, C., Ding, J., et al. (2010) · Nature Genetics · doi:10.1038/ng.689 · Cited by 359
Keratinocyte overexpression of IL-17C promotes psoriasiform skin inflammation
Johnston, A., Fritz, Y., Dawes, S. M., Diaconu, D., Al-Attar, P. M., Guzman, A. M., Chen, C. S., Fu, W., Gudjonsson, J. E., McCormick, T. S., et al. (2013) · The Journal of Immunology · doi:10.4049/jimmunol.1201505 · Cited by 308
Genetic Epidemiology of Psoriasis
Gupta, R., Debbaneh, M. G., & Liao, W. J. (2014) · Current Dermatology Reports · doi:10.1007/s13671-013-0066-6 · Cited by 167
Consensus Guidelines for the Management of Plaque Psoriasis
Hsu, S. (2012) · Archives of Dermatology · doi:10.1001/archdermatol.2011.1410 · Cited by 161
Russell, C. B., Rand, H., Bigler, J., Kerkof, K., Timour, M., Bautista, E., Krueger, J. G., Salinger, D. H., Welcher, A. A., & Martin, D. A. (2014) · The Journal of Immunology · doi:10.4049/jimmunol.1301737 · Cited by 160
Genome-wide association scan yields new insights into the immunopathogenesis of psoriasis
Elder, J. (2009) · Genes and Immunity · doi:10.1038/gene.2009.11 · Cited by 158
Papp, K. A., Reid, C., Foley, P. A., Sinclair, R. D., Salinger, D. H., Williams, G., Dong, H., Krueger, J. G., Russell, C. B., & Martin, D. A. (2012) · Journal of Investigative Dermatology · doi:10.1038/jid.2012.163 · Cited by 143
Self-citationRevicki, D. A., Willian, M. K., Menter, A., Saurat, J. ‐., Harnam, N., & Kaul, M. (2008) · Dermatology · doi:10.1159/000113150 · Cited by 121
Self-citationViswanathan, H. N., Chau, D., Milmont, C. E., Yang, W., Erondu, N., Revicki, D. A., & Klekotka, P. A. (2014) · Journal of Dermatological Treatment · doi:10.3109/09546634.2014.943687 · Cited by 81
Self-citationThe global burden of psoriatic skin disease
Goff, K. L., Karimkhani, C., Boyers, L. N., Weinstock, M. A., Lott, J. P., Hay, R. J., Coffeng, L. E., Norton, S. A., Naldi, L., Dunnick, C. A., et al. (2015) · British Journal of Dermatology · doi:10.1111/bjd.13715 · Cited by 73
Self-citationLi, J., Li, D., & Tan, Z. (2004) · Current Medical Science · doi:10.1007/bf02832018 · Cited by 47
Self-citation
Cited by
Griffiths, C. E. M., Armstrong, A. W., Gudjonsson, J. E., & Barker, J. N. W. N. (2021) · The Lancet · doi:10.1016/s0140-6736(20)32549-6 · Cited by 2,383
Self-citationPathophysiology, Clinical Presentation, and Treatment of Psoriasis: A Review
Armstrong, A. W., & Read, C. (2020) · JAMA · doi:10.1001/jama.2020.4006 · Cited by 2,335
Self-citationPsoriasis pathogenesis and the development of novel targeted immune therapies
Hawkes, J. E., Chan, T. C., & Krueger, J. G. (2017) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2017.07.004 · Cited by 972
Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with biologics
Menter, A., Strober, B. E., Kaplan, D. H., Kivelevitch, D., Prater, E. F., Stoff, B., Armstrong, A. W., Connor, C., Cordoro, K. M., Davis, D. M. R., et al. (2019) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2018.11.057 · Cited by 969
Self-citationGreb, J. E., Goldminz, A. M., Elder, J. T., Lebwohl, M. G., Gladman, D. D., Wu, J. J., Mehta, N. N., Finlay, A. Y., & Gottlieb, A. B. (2016) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2016.82 · Cited by 922
Self-citation
Metadata
- Authors
- Lebwohl, M., Strober, B., Menter, A., Gordon, K., Weglowska, J., Puig, L., Papp, K., Spelman, L., Toth, D., Kerdel, F., Armstrong, A. W., Stingl, G., Kimball, A. B., Bachelez, H., Wu, J. J., Crowley, J., Langley, R. G., Blicharski, T., Paul, C., Lacour, J.-P., Tyring, S., Kircik, L., Chimenti, S., Callis Duffin, K., Bagel, J., Koo, J., Aras, G., Li, J., Song, W., Milmont, C. E., Shi, Y., Erondu, N., Klekotka, P., Kotzin, B., & Nirula, A.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2015-10
- Volume
- 373
- Issue
- 14
- Pages
- 1318-1328
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2326643498
- Cited by
- 828
- References
- 21
- FWCI
- 36.96
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.